Spierings E, et al.2008
The health claims for functional foods and the identification of their active functional ingredients mandates the documentation of any potential toxicity they may present. Phase 1 clinical trials are used to make the initial safety assessment of compounds with potential medical uses.
Open-label controlled: Oligonol® was orally administered to healthy subjects twice per day for 14 days. Its effect on various laboratory parameters assessing safety were measured at 7-day intervals. Adverse events were monitored at 7-day intervals..
Laboratory measurements and adverse effects reported after 7 and 14 days of supplementation with Oligonol®:
“This data supports previous data in animals and human beings that shows Oligonol® is a safe, well-tolerated nutritional supplement.”